Role of the autonomic nervous system and neuropeptides in the development of obesity in humans: Targets for therapy?

Current Pharmaceutical Design

Volumn 14, Issue 18, 2008, Pages 1815-1820

  Greenfield, Jerry R ^a   Campbell, Lesley V ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Autonomic nervous system; Insulin resistance; Neuropeptide Y; Obesity; Overweight; Sympathetic nervous system; Y2 receptor

Indexed keywords

ANTIOBESITY AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID 1 RECEPTOR; INSULIN; LEPTIN; NEUROPEPTIDE Y; NEUROPEPTIDE Y2 RECEPTOR; PHENTERMINE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABDOMINAL OBESITY; ADRENERGIC STIMULATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; HORMONAL REGULATION; HUMAN; INSULIN RESISTANCE; LIPID STORAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR DOWN REGULATION; REVIEW; SYMPATHETIC TONE; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; NEUROPEPTIDES; OBESITY;

EID: 47349128669     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784746716     Document Type: Review

References (61)

1. Chisholm DJ, Campbell LV, Kraegen EW. Pathogenesis of the insulin resistance syndrome (syndrome X). Clin Exp Pharmacol Physiol 1997; 24: 782-4.
2. Kraegen EW, Cooney GJ. The role of free fatty acids in muscle insulin resistance. Diabetes Annu 1999; 12: 141-59.
3. Greenfield JR, Campbell LV. Insulin resistance and obesity. Clin Dermatol 2004; 22: 289-95.
4. Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Ann N Y Acad Sci 2006; 1083: 129-52.
5. Eikelis N, Esler M. The neurobiology of human obesity. Exp Physiol 2005; 90: 673-82.
6. Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007; 25: 909-20.
7. Malliani A, Pagani M, Lombardi F, Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation 1991; 84: 482-92.
8. Landsberg L. Obesity and the insulin resistance syndrome. Hypertens Res 1996; 19(Suppl 1): S51-5.
9. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994-1003.
10. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal I, Maggioni A, et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28: 2915-23.
11. Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs 2006; 66: 1625-56
12. Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 2006; 5: 919-31.
13. Grassi G. Sympathetic overdrive and cardiovascular risk in the Metabolic Syndrome. Hypertens Res 2006; 29: 839-47.
14. Rayner DV, Trayhurn P. Regulation of leptin production: sympathetic nervous system interactions. J Mol Med 2001; 79: 8-20.
15. Arone LJ, Mackintosh R, Rosenbaum M, Leibel RL, Hirsch J. Autonomic nervous system activity in weight gain and weight loss. Am J Physiol 1995; 269: R222-5.
16. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20: 805-75.
17. Bray GA. Reciprocal relation of food intake and sympathetic activity: experimental observations and clinical implications. Int J Obes Relat Metab Disord 2000; 24(Suppl 2): S8-17.
18. Tsujii S, Bray GA. A beta-3 adrenergic agonigt (BRL-37, 344) decreases food intake. Physiol Behav 1998; 63: 723-8.
19. Bowers RR, Festuccia WT, Song CK, Shi H, Migliorini RH, Bartness TJ. Sympathetic innervation of white adipose tissue and its regulation of fat cell number. Am J Physiol Regul Integr Comp Physiol 2004; 286: R1167-75.
20. Scheidegger K, O'Connell M, Robbins DC, Danforth E, Jr. Effects of chronic beta-receptor stimulation on sympathetic nervous system activity, energy expenditure, and thyroid hormones. J Clin Endocrinol Metab 1984; 58: 895-903.
21. Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK, et al. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002; 297: 843-5.
22. Acheson KJ, Ravussin E, Schoeller DA, Christin L, Bourquin L, Baertachi P, et al. Two-week stimulation or blockade of the sympathetic nervous system in man: influence on body weight, body composition, and twenty four-hour energy expenditure. Metabolism 1988; 37: 91-8.
23. Lamont LS, Brown T, Riebe D, Caldwell M. The major components of human energy balance during chronic beta-adrenergic blockade. J Cardiopulm Rehabil 2000; 20: 247-50.
24. Deacon SP. The effects of atenolol and propranolol upon lipolysis. Br J Clin Pharmacol 1978; 5: 123-5.
25. Castellano M, Bohm M. The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension 1997; 29: 715-22.
26. Muscelli E, Pereira JA, Lazarin MACT, da Silva CA, Pareja JC, Saad MJA. Lack of insulin inhibition on insulin secretion in non-diabetic morbidly obese patients. Int J Obes 2001; 25: 798-804.
27. Muscelli E, Emdin M, Natali A. Pratali L, Camastra S, Gastaldelli A, et al. Autonomic and hemodynamic responses to insulin in lean and obese humans. J Clin Endocrinol Metab 1998; 83: 2094-90.
28. Paolisso G, Manzella D, Rizzo MR, Barbieri M, Varricchio G, Gambardella A, et al. Effects of insulin on the cardiac autonomic nervous system in insulin-resistant states. Clin Sci (Lond) 2000; 98: 129-36.
29. Paolisso G, Manzella D, Tagliamonte MR, Rizzo MR, Gambardella A, Varricchio M. Effects of different insulin infusion rates on heart rate variability in lean and obese subjects. Metabolism 1999; 48: 755-62.
30. Tentolouris N, Tsigos C, Perea D, Koukou E, Kyriaki D, Kitsou E, et al. Differential effects of high-fat and high-carbohydrate isoenergetic meals on cardiac autonomic nervous system activity in lean and obese women. Metabolism 2003; 52:1426-32.
31. Tataranni PA, Young JB, Bogardus C, Ravussin E. A low sympathoadrenal activity is associated with body weight gain and development of central adiposity in Pima Indian men. Obes Res 1997; 5: 341-7.
32. Bergholm R, Westerbacka, J, Vehkavaara S, Seppala-Lindroos A, Goto T, Yki-Jarvinen H. Insulin sensitivity regulates autonomic control of heart rate variation independent of body weight in normal subjects. J Clin Endocrinol Metab 2001; 86: 1403-9.
33. Kriketos AD, Greenfield JR, Peake PW, Furler SM, Denyer GS, Charlesworth JA, et al. Inflammation, insulin resistance, and adiposity. A study of first-degree relatives of type 2 diabetic subjects. Diabetes Care 2004; 27: 2033-40.
34. Kriketos AD, Denyer GS, Thompson CH, Campbell LV. Intramyocellular lipid is not significantly increased in healthy young insulin resistant first-degree relatives of diabetic subjects. Diabetes Care 2005; 28: 2332-3.
35. Fiorentini A, Perciaccante A, Paris A, Serra P, Tubani L. Circadian rhythm of autonomic activity in non diabetic offsprings of type 2 diabetic patients. Cardiovasc Diabetol 2005; 4: 15.
36. Laitinen T, Vauhkonen IK, Niskanen LK, Hartikainen JE, Lansimies EA, Uusitupa MI, et al. Power spectral analysis of heart rate variability during hyperinsulinemia in nondiabetic offspring of type 2 diabetic patients: evidence for possible early autonomic dysfunction in insulin-resistant subjects. Diabetes 1999; 48: 1295-9.
37. Frontoni S, Bracaglia D, Baroni A, Pellegrini F, Perna M, Cicconetti E, et al. Early autonomic dysfunction in glucose-tolerant but insulin-resistant offspring of type 2 diabetic patients. Hypertension 2003; 41: 1223-7.
38. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanism in hypertension. Circulation 2003; 108:3097-101.
39. Watanabe T, Nomura M, Nakayasu K, Kawano T, Ito S, Nakaya Y. Relationships between thermic effect of food, insulin resistance and autonomic nervous activity. J Med Invest 2006; 53: 153-8.
40. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-81.
41. Tremblay A. Differences in fat balance underlying obesity. Int J Obes Relat Metab Disord 1995; 19 Suppl 7: S10-S4; discussion S5-6.
42. Heilbronn LK, Gregersen S, Shirkhedkar D, Hu D, Campbell LV. Impaired fat oxidation after a single high-fat meal in insulin-sensitive nondiabetic individuals with a family history of type 2 diabetes. Diabetes 2007; 56: 2046-53.
43. Bobbioni-Harsch E, Sztajzel J, Barthassat V, Lehmann TN, Sievert K, Chassot G, et al. The effect of insulin on cardiac autonomic balance predicts weight reduction after gastric bypass. Diabetologia 2005; 48: 1258-63.
44. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation 2002; 106: 2533-6.
45. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex. function in obese normotensives. J Hypertens 2004; 22: 2363-9.
46. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993; 133: 1753-8.
47. Sainsbury A, Rohner-Jeanrenaud F, Cusin I, Zakrzewska KE, Halban PA, Gaillard RC, et al. Chronic central neuropeptide y infusion in normal rats: status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia 1997; 40: 1269-77.
48. Parker E, Van Heek M, Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur J Pharmacol 2002; 440: 173-87.
49. Kamiji MM, Inui A. Neuropeptide y receptor selective ligands in the treatment of obesity. Endocr Rev 2007; 28: 664-84.
50. Powell DR. Obesity drugs and their targets: correlation of mouse knockout phenotypes with drug effects in vivo. Obes Rev 2006; 7: 89-108.
51. Erondu N, Addy C, Lu K, Mallick M, Musser B, Gantz I, et al. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity (Silver Spring) 2007; 15: 2027-42.
52. Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006; 4: 275-82.
53. Erondu N, Wadden T, Gantz I, Musser B, Nguyen AM, Bays H, et al. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-caloric diet-induced weigh~loss. Obesity (Silver Spring) 2007; 15: 895-905.
54. Lin E, Zhang L, Sainsbury A, Herzog H. Y2, Y4 receptors and obesity. Expert Rev Endocrinol Metab 2007; 2: 163-73.
55. Sainsbury A, Schwarzer C, Couzens M, Fetissov S, Furtinger S, Jenkins A, et al. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci USA 2002; 99: 8938-43.
56. Sainsbury A, Schwarzer C, Couzens M, Herzog H. Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Diabetes 2002; 51: 3420-7.
57. Naveilhan P, Svensson L, Nystrom S, Ekstrand AJ, Ernfors P. Attenuation of hypercholesterolemia and hyperglycemia in ob/ob mice by NPY Y2 receptor ablation. Peptides 2002; 23: 1087-91.
58. Lavebratt C, Alpman A, Persson B, Amer P, Hoffstedt J. Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men. Int J Obes (Lond) 2006; 30: 453-9.
59. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007; 13: 803-11.
60. Vettor R, Pagano C, Granzotto M, Englaro P, Angeli P, Blum WF, et al. Effects of intravenous neuropeptide Y on insulin secretion and insulin sensitivity in skeletal muscle in normal rats. Diabetologia 1998; 41: 1361-7.
61. Campbell LV. The thrifty gene hypothesis: maybe everyone is right? Int J Obes (Lond) 2008; 32: 723-4.